Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14310734 | 0.86 | HPGDS (0.43) | KIF11HPGDSLTA4HNOTUMBACE1 | |
| SCHEMBL9258818 | 0.83 | NOTUM (0.58) | HPGDSLTA4HNOTUMBRD4NPC1 | |
| SCHEMBL3964365 | 0.82 | HPGDS (0.58) | HPGDSLTA4HNOTUMBACE1BACE2 | |
| SCHEMBL13222357 | 0.79 | LTA4H (0.50) | KIF11HPGDSLTA4HNOTUMNPC1 | |
| SCHEMBL16159319 | 0.78 | HPGDS (0.55) | HPGDSLTA4HNOTUMBACE1BACE2 | |
| SCHEMBL24037525 | 0.77 | S1PR1 (0.41) | KIF11HPGDSLTA4HNOTUMNPC1 | |
| SCHEMBL3098624 | 0.77 | RAB9A (0.51) | HPGDSLTA4HNOTUMBACE1NPC1 | |
| SCHEMBL14752258 | 0.77 | HPGDS (0.39) | KIF11HPGDSLTA4HBACE1BACE2 | |
| SCHEMBL16383003 | 0.76 | HPGDS (0.43) | HPGDSLTA4HNOTUMBACE1BACE2 | |
| SCHEMBL2152660 | 0.75 | HPGDS (0.61) | HPGDSLTA4HBACE1BACE2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11325930-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10947259-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | KIF11 2289/4885HPGDS 378/4885LTA4H 3261/4885 |
| US-11325930-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
| US-10947259-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | KIF11 2289/4885HPGDS 378/4885LTA4H 3261/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | KIF11 4156/4885HPGDS 1325/4885LTA4H 353/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | KIF11 2289/4885HPGDS 378/4885LTA4H 3261/4885 |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | MKI67, TYMP, PCNA | KIF11 2289/4885HPGDS 378/4885LTA4H 3261/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | KIF11 2289/4885HPGDS 378/4885LTA4H 3261/4885 |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, P2RX3 | KIF11 4156/4885HPGDS 1325/4885LTA4H 353/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | KIF11 4103/4885HPGDS 1375/4885LTA4H 418/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KIF11 3487/4885HPGDS 469/4885LTA4H 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.